CloneID: 1696
Antigen Long Description: 1696 was prepared by generating a hybridoma cell line, fusing myeloma cells with splenocytes derived from BALB/c mice immunized with HIV-1 PR in the presence of Freund's adjuvant.
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: O90777
Specificity Statement: 1696 binds to HIV-PR of both HIV-1 and HIV-2 (IgG 1696: HIV-1 PR pH5.7 ~350 uM; pH7.4 ~100 nM - HIV-2 PR pH5.7 no measurable interaction; pH7.4 ~30 nM -- Fab 1696: HIV-1 PR pH5.7 ~410 nM; pH7.4 ~130 nM - HIV-2 PR pH5.7 no measureable interaction; pH7.4 ~40 nM-- determined by ELISA). The antibody binds to the N-terminal region of the enzyme, and binding is inhibited by the peptide fragment PQITLWQ which represents residues 1-7. Western blot binding assays show that 1696 recognizes the mature and processed form of the enzyme, but not the precursor which possesses 20 residues upstream from the cleavage site. The N-terminus has a well conserved structure between HIV-1 PR and HIV-2 PR. HIV-PR is a homodimeric apartate protease that specifically cleaves the viral Gag and Gag/Pol polyprotein precursor. A correlation has been observed between the activity of the protease and the degree of infectivity, and so this protein is a major antiviral target.
Application Notes (Clone): 1696 mAb can inhibit the catalytic activity of both HIV-1 and HIV-2 HIV-PR (1696 IgG HIV-1 PR IC50 ~0.6 nM; HIV-2 PR IC50 ~1.5 nM -- 1696 Fab HIV-1 PR IC50 ~1.1 nM; HIV-2 PR IC50 ~2.6 nM). Inhibition by 1696 is mediated by the destabilization of the of the active form of the active HIV-PR homodimer through binding to the N-terminus, which constitutes a large percentage of the interface between the monomers. The Fab fragment was generated by incubation of the antibody with pepsin. Binding constants of 1696 can be determined by ELISA. 1696 shows reactivity to the mature processed HIV-PR and not to the precursor by WB.